TrialPath
Recruiting

Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis

NCT07566351 · Horus University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Clinical Study to Compare the Possible Efficacy and Safety of Roflumilast and Desloratadine as Adjuvant Therapy for Rheumatoid Arthritis
About this study
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial inflammation, progressive joint destruction, and impaired quality of life. Despite the availability of conventional disease-modifying antirheumatic drugs (DMARDs), a subset of patients continues to have persistent disease activity and inflammatory burden. Phosphodiesterase-4 inhibitors and antihistamines have demonstrated potential anti-inflammatory and immunomodulatory effects that may be beneficial in rheumatoid arthritis. Roflumilast, a selective phosphodiesterase-4 inhibitor, reduces the production of pro-inflammatory cytokines, while desloratadine has been shown to exhibit additional anti-inflammatory properties beyond its antihistaminic effect. This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of roflumilast or desloratadine as add-on therapy to standard DMARD treatment in patients with rheumatoid arthritis. Eligible participants will be randomized into three parallel groups to receive either roflumilast, desloratadine, or placebo for a duration of three months. Clinical assessments will include evaluation of disease activity scores, inflammatory biomarkers, and patient-reported outcomes. Safety and tolerability will be monitored throughout the study period. The findings of this study may provide evidence for novel adjunctive therapeutic strategies in the management of rheumatoid arthritis.
Eligibility criteria
Inclusion Criteria: * Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria. * Disease activity score in 28 joints (DAS28) greater than 2.6. * Age between 18 and 60 years. * Male and female patients. * Patients receiving methotrexate in addition to standard conventional therapy. Exclusion Criteria: Exclusion Criteria: * Patients with renal or hepatic disease. * Known hypersensitivity to the study medications. * Current use of antioxidant supplements. * History of psychiatric disorders. * Use of oral prednisolone at a dose greater than 15 mg per day. * Current treatment with biological disease modifying antirheumatic drugs. * Pregnant or breastfeeding patients. * History of cardiac arrhythmias or prolonged QT interval. * Use of medications known to prolong the QT interval.
Study design
Enrollment target: 90 participants
Allocation: randomized
Masking: quadruple
Age groups: adult
Timeline
Starts: 2026-04-23
Estimated completion: 2027-07
Last updated: 2026-05-12
Interventions
Drug: RoflumilastDrug: DesloratadineDrug: Placebo
Primary outcomes
  • • Change in Disease Activity Score (DAS28) (Baseline to 12 weeks)
Sponsor
Horus University · other
Contacts & investigators
ContactAmira Mashaly · contact · amashaly@horus.edu.eg · 01028275001
All locations (1)
Faculty of Pharmacy, Horus University in EgyptRecruiting
Damietta, Damietta Governorate, Egypt
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis · TrialPath